Top-Searched Lab Tests
Explore Conditions
Explore Biomarkers
Explore Diagnostic Labs
New Lab Tests
| Test Name | Methodology | Specimen | TAT | Lab |
|---|---|---|---|---|
| Precivity-ApoE™ | Mass Spectrometry | Whole Blood | 10 d | C2N Diagnostics |
| PrecivityAD2™ | Mass Spectrometry | Plasma | 10 d | C2N Diagnostics |
| PrecivityAD® | Mass Spectrometry | Whole Blood | 10 d | C2N Diagnostics |
| Pathlight™ Multi-cancer MRD test | NGS | Whole Blood, Tissue | 2-3 w | Saga Diagnostics |
| Cancerguard® Multi-Cancer Early Detection Test | Composite | Whole Blood | 10-14 d | Exact Sciences |
Precivity-ApoE™
Methodology:Mass Spectrometry
Specimen:Whole Blood
TAT:10 d
Lab:C2N Diagnostics
PrecivityAD2™
Methodology:Mass Spectrometry
Specimen:Plasma
TAT:10 d
Lab:C2N Diagnostics
PrecivityAD®
Methodology:Mass Spectrometry
Specimen:Whole Blood
TAT:10 d
Lab:C2N Diagnostics
Pathlight™ Multi-cancer MRD test
Methodology:NGS
Specimen:Whole Blood, Tissue
TAT:2-3 w
Lab:Saga Diagnostics
Cancerguard® Multi-Cancer Early Detection Test
Methodology:Composite
Specimen:Whole Blood
TAT:10-14 d
Lab:Exact Sciences
Featured Companion Diagnostics
| Test Name | Methodology | Specimen | TAT | Lab |
|---|---|---|---|---|
| xT CDx | NGS | Tissue, Whole Blood, Saliva | 10-14 d | Tempus AI |
| Vysis Chronic Lymphocytic Leukemia (CLL) Panel | Chromosomal / Cytogenetics | Whole Blood, Bone Marrow | 5 d | MPLN |
| PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) | Chromosomal / Cytogenetics | Tumor Tissue | — | ARUP Laboratories |
| nAbCyte™ Anti‑AAVRh74var HB‑FE Assay (nAbCyte Assay) | Other | Serum | 7-10 d | Labcorp |
| MyChoice® CDx Myriad HRD Companion Diagnostic Test | NGS | Tissue | 14 d | Myriad Genetics |
xT CDx
Methodology:NGS
Specimen:Tissue, Whole Blood, Saliva
TAT:10-14 d
Lab:Tempus AI
Vysis Chronic Lymphocytic Leukemia (CLL) Panel
Methodology:Chromosomal / Cytogenetics
Specimen:Whole Blood, Bone Marrow
TAT:5 d
Lab:MPLN
PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
Methodology:Chromosomal / Cytogenetics
Specimen:Tumor Tissue
TAT:—
Lab:ARUP Laboratories
nAbCyte™ Anti‑AAVRh74var HB‑FE Assay (nAbCyte Assay)
Methodology:Other
Specimen:Serum
TAT:7-10 d
Lab:Labcorp
MyChoice® CDx Myriad HRD Companion Diagnostic Test
Methodology:NGS
Specimen:Tissue
TAT:14 d
Lab:Myriad Genetics
Featured Sponsored Testing
| Program Name | Therapeutic Area(s) | Condition | Lab |
|---|---|---|---|
| FCSNext | Endocrinology | Familial Chylomicronemia Syndrome (FCS) | Ambry Genetics |
| NovoDETECT Primary Hyperoxaluria Panel | Nephrology | Primary Hyperoxaluria (PH) | Blueprint Genetics |
| Lysosomal Disorders Testing Pathway | Metabolic | Mucopolysaccharidosis Type I (MPS I) (Hurler-Scheie Syndrome), Mucopolysaccharidosis Type II (MPSII) (Hunter Syndrome) | Revvity Omics, Inc. |
| Renasight™ Genetic Kidney Panel | Nephrology | Chronic Kidney Disease (CKD), APOL1-Mediated Kidney Disease (AMKD) | Natera |
| Invitae Primary Immunodeficiency Panel | Immunology | Activated PI3K-Delta Syndrome | Invitae | Labcorp |
FCSNext
Therapeutic Area(s):Endocrinology
Condition:Familial Chylomicronemia Syndrome (FCS)
Lab:Ambry Genetics
NovoDETECT Primary Hyperoxaluria Panel
Therapeutic Area(s):Nephrology
Condition:Primary Hyperoxaluria (PH)
Lab:Blueprint Genetics
Lysosomal Disorders Testing Pathway
Therapeutic Area(s):Metabolic
Condition:Mucopolysaccharidosis Type I (MPS I) (Hurler-Scheie Syndrome), Mucopolysaccharidosis Type II (MPSII) (Hunter Syndrome)
Lab:Revvity Omics, Inc.
Renasight™ Genetic Kidney Panel
Therapeutic Area(s):Nephrology
Condition:Chronic Kidney Disease (CKD), APOL1-Mediated Kidney Disease (AMKD)
Lab:Natera
Invitae Primary Immunodeficiency Panel
Therapeutic Area(s):Immunology
Condition:Activated PI3K-Delta Syndrome
Lab:Invitae | Labcorp